Mast cell mediators in relation to dengue severity: A systematic review and meta-analysis

Nourin Ali Sherif1,2, Ahmad Helmy Zayan2,3, Aya Hesham Elkady2,4

  • 1Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Reviews in Medical Virology
|November 12, 2019
PubMed
Abstract

Insights

Mast cells (MCs) release mediators like VEGF and chymase, influencing dengue severity. While VEGF levels showed no significant difference in early dengue fever stages, chymase was higher in severe dengue hemorrhagic fever.

Area of Science:

  • Immunology
  • Virology
  • Pathogenesis

Background:

  • Mast cells (MCs) degranulate, releasing mediators like vascular endothelial growth factor (VEGF), chymase, tryptase, histamine, and cytokines.
  • These mediators play crucial roles in the severity of dengue virus infections.

Purpose of the Study:

  • To investigate the role of mast cells (MCs) and their mediators in the severity of dengue infection.

Main Methods:

  • A meta-analysis was conducted using data from 24 relevant in vivo and in vitro studies.
  • Searches were performed across 10 databases up to August 2016, with analysis using R version 3.5.0.

Main Results:

  • Infected mice/cells showed higher MC product release.
  • MC stabilizers and antihistamines reduced vascular permeability.
  • VEGF levels were not significantly different in early dengue fever (DF) vs. dengue hemorrhagic fever (DHF).
  • VEGF levels were significantly increased in dengue shock syndrome (DSS) compared to controls.
  • Chymase levels were significantly higher in DHF compared to DF during the acute phase.

Conclusions:

  • VEGF and chymase are mediators in dengue pathogenesis.
  • Limited data currently support their definitive role in severe dengue cases.
  • Further research is required to fully elucidate the function of other mediators in dengue severity.

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Allergic Reactions02:06

Allergic Reactions

Overview
31.8K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K